Skip to main content

Genomics of rare genetic diseases—experiences from India


Home to a culturally heterogeneous population, India is also a melting pot of genetic diversity. The population architecture characterized by multiple endogamous groups with specific marriage patterns, including the widely prevalent practice of consanguinity, not only makes the Indian population distinct from rest of the world but also provides a unique advantage and niche to understand genetic diseases. Centuries of genetic isolation of population groups have amplified the founder effects, contributing to high prevalence of recessive alleles, which translates into genetic diseases, including rare genetic diseases in India.

Rare genetic diseases are becoming a public health concern in India because a large population size of close to a billion people would essentially translate to a huge disease burden for even the rarest of the rare diseases. Genomics-based approaches have been demonstrated to accelerate the diagnosis of rare genetic diseases and reduce the socio-economic burden. The Genomics for Understanding Rare Diseases: India Alliance Network (GUaRDIAN) stands for providing genomic solutions for rare diseases in India. The consortium aims to establish a unique collaborative framework in health care planning, implementation, and delivery in the specific area of rare genetic diseases. It is a nation-wide collaborative research initiative catering to rare diseases across multiple cohorts, with over 240 clinician/scientist collaborators across 70 major medical/research centers. Within the GUaRDIAN framework, clinicians refer rare disease patients, generate whole genome or exome datasets followed by computational analysis of the data for identifying the causal pathogenic variations. The outcomes of GUaRDIAN are being translated as community services through a suitable platform providing low-cost diagnostic assays in India. In addition to GUaRDIAN, several genomic investigations for diseased and healthy population are being undertaken in the country to solve the rare disease dilemma.

In summary, rare diseases contribute to a significant disease burden in India. Genomics-based solutions can enable accelerated diagnosis and management of rare diseases. We discuss how a collaborative research initiative such as GUaRDIAN can provide a nation-wide framework to cater to the rare disease community of India.


Population architecture and genetic diversity in India

India is the sixth largest country in the world in terms of its geographical area and the second largest country in population density. The people of the country are diverse in terms of their social, linguistic, cultural, and racial backgrounds. Evolutionarily, the Indian subcontinent has been a corridor for different migratory waves arising from Africa, through land as well as coastline routes [1, 2]. Genetic studies have shown that there are four distinct ancestral groups in mainland India, and a separate ancestry in the Andaman and Nicobar islands [3, 4]. On the basis of ethno-racial grounds, the four major groups in India can be classified as the Caucasoids, Australoids, Mongoloids, and Negritos. The Indian population comprises of over 4000 anthropologically distinct groups speaking more than 300 languages [5], suggesting that linguistic stratification is highly tied to the geographical niches of each sub-population [6,7,8,9,10]. Further, the population is also sub-classified into tribes and castes based on cultural and social backgrounds [8]. These different layers of population stratification have led to the richness in diversity of India.

The genetic diversity is well reflected in the mitochondrial DNA (mtDNA), Y chromosomes, and candidate genes/markers, which have provided a fair understanding of the relatedness and divergence of specific communities or tribes of India [6, 8, 11,12,13,14,15,16,17]. The prevalence of consanguinity in marriages, due to cultural and social practices, in many sub-populations in India has led to the accumulation of genetic traits within communities [3, 18]. Studies have shown a high level of relatedness within subgroups suggesting accumulation of deleterious variations [19, 20]. These studies indicate that the ancestors of different subpopulations in India may have arisen from different waves of migration with relatively limited founding members, implying the source of genetic distinction, while regionally and culturally distinct groups continue to be genetically unique due to the practices of inbreeding.

A national genome-wide approach to understand the population architecture and look for markers specific to the Indian subcontinent was undertaken by the Indian Genome Variation (IGV) consortium, which used single-nucleotide polymorphisms (SNPs) to type 900 genes from over 1800 individuals across 55 endogamous populations. High heterozygosity values, varying allele frequencies, and common polymorphic haplotypes of sub-populations were shown to underline the heterogeneity within the Indian population. Additionally, unique mutations were discovered within the subcontinent, with concomitant founder effects [10, 21, 22].

The findings of the IGV consortium have led to the identification of specific markers and better understanding of genotype-phenotype correlations in Indian sub-populations. The phenotypically distinct outcomes of sub-population specific genotypes could be shown in susceptibility or resistance towards Plasmodium falciparum [23,24,25,26,27], risk of contracting glaucoma [28], homocysteine levels [29], and risk of developing high-altitude pulmonary edema [30, 31], among other examples. Further, case-control studies in ethnically matched groups as defined by IGV consortium allowed identification of Indian-specific susceptibility markers in genes causing Parkinson’s disease, Wilson disease, and albinism [32,33,34,35]. Sub-population-specific responses to various drugs have also been documented, based on differences in the allele frequencies of variants in metabolizer enzyme genes, across various ethnicities in India [36,37,38].

Thus, the extensive genetic heterogeneity and the endogamous cultural practices clearly suggest that there is a need to demarcate genetic affinities and distinctions among sub-populations. These findings also underscore the genetic distinction of the Indian population from the populations of other countries, warning against the imputation of genetic information from other populations. Evidently, a generalization of the population architecture can lead to erroneous interpretations in clinical settings.

Genetic diversity of India: a driver of high-genetic disease prevalence

India, being a melting pot of genetic diversity, is also home to strict inbreeding practices and founder effects, which have resulted in the accumulation of deleterious genetic variations [39]. The reported prevalence of birth defects in India is 64.4 per 1000 live births [40]. The high genetic burden in India has been highlighted by independent studies [41,42,43,44]. The lack of a national newborn screening program until recently has led to a distending proportion of the Indian population ailing with genetic diseases [45]. Inborn errors of metabolism (IEM), which is a nation-wide issue, can be addressed on being identified at the neonatal stages [46, 47]. Hemoglobinopathies including sickle cell anemia, thalassemia, pose a significant burden in India, and are known in specific sub-populations [48, 49]. Down syndrome is another genetic disorder, which is the major cause of mental retardation, with a frequency of approximately 1 in 1000 births [50]. A database for cataloging genetic diseases, the Indian Genetic Disease Database (IGDD) has been set up, version 1.0 of which housed information on variants in 63 genes corresponding to 52 genetic diseases known in the Indian population [51]. The database is freely available and currently holds information on over 100 genetic diseases from around 3500 patients [52].

What is striking, apart from the high prevalence of monogenic diseases, is the heterogeneity in the outcome of the same disease. The clinical heterogeneity in blood disorders in India has been attributed to subpopulation-specific variations and allele frequencies [53,54,55,56,57]. Similarly, the phenotypic spectrum of Spinocerebellar ataxias (SCA) and their pathogenic variants have been shown across Indian subpopulations [42]. Ethnicity-dependent mitochondrial haplotypes have also been shown to give rise to differences in penetrance in the mitochondrial disease Leber’s hereditary optic neuropathy (LHON) [58]. Population-specific genetic variations and susceptibility to diseases have been shown in hereditary cardiomyopathy [59, 60] and drug/toxin metabolism [61]. The genetic heterogeneity, which was thought as an advantage, is, in fact, contributing to the high prevalence of genetic diseases in India. Several studies have also shown that the genetic variations and frequency information observed in population worldwide are not fully relevant to the Indian context [62,63,64]. Thus, it is important to document the true extent of genetic variation and burden of genetic diseases in Indian settings.

A number of genome-scale datasets of Indians have surfaced in recent years. These include an initiative by the IGV consortium of six laboratories affiliated to the Council of Scientific and Industrial Research (CSIR) with other key players, that typed SNPs and known markers scattered among 1000 genes [10, 21, 22, 65]. This was also followed by whole-genome sequencing of Indians from the USA [66] and from India [67, 68], in addition to several large-scale projects which sequenced healthy individuals who are descendants of Indian immigrants and from specific Indian sub-populations [69,70,71,72]. Genomes of healthy individuals from different parts of India were sequenced subsequently [73,74,75,76,77]. These initiatives have culminated in efforts to meta-analyze and integrate datasets, which has resulted in resources such as the South Asian Genomes and Exomes (SAGE) [76] and INDian EXome database (INDEX-db) [78]. In addition, several disease or application specific databases developed in India provide a rich source of information about the genetic diversity and underlying genetic disease prevalence in India (Table 1).

Table 1 Details of publicly available resources that can aid in rare genetic disease research in India

It is to be noted that given the heterogeneity shown by IGV and other studies, the number of Indian genomes and exomes that are available till date under-represents the peninsula’s diversity. This gap in the availability of baseline genetic information can hence act as a barrier in understanding the causes of diseases that are prevalent in the country and calls for a nation-wide genome project, as being undertaken in other parts of the world [82].

Main text

Rare diseases: a significant burden for India

Rare diseases or orphan diseases are defined as those which afflict a minimal fraction of a population. An attempt to identify the parameters that can be used to define a rare disease was made by the ‘Rare Disease Terminology & Definitions Used in Outcomes Research Working Group.’ The study concluded that a disease with the average global prevalence of 40–50 cases per 100,000 people can be called as a rare disease [83]. The Orphan Drug Act (ODA) of 1983 [84] under the US law, which was instrumental in gathering attention towards rare diseases [85], defined a rare disease in the USA as a disease affecting fewer than 200,000 people of the total population. The council of the European Union defined a rare disease as 5 in 10,000 [86]. The rare disease prevalence for different countries thus varies. For instance, the respective rare disease prevalence numbers are 65 in 100,000 in Brazil [87], 1 in 2500 in Japan [83], and 33.2 per 100,000 in Taiwan [88].

The pervasive endogamy and founder effects in sub-populations have led to a high prevalence of autosomal recessive rare genetic diseases in India, compared to other parts of the world. While there is no appropriate standard definition to describe a rare disease in India, Indian Council of Medical Research (ICMR) has defined a disease as rare if it affects less than 1 person in 2500 individuals [89]. The Organization for Rare Diseases India (ORDI) has suggested a threshold of 1 in 5000 for defining rare diseases in India [90]. About 5000–8000 rare diseases have been documented all over the globe accounting for up to 6–8% of the global population [86]. Approximately, 40% of the rare diseases can be attributed to genetic factors [91]. These diseases together contribute to a significant number of individuals and the disease burden in a populous country such as India.

The estimation of the prevalence of rare genetic diseases across India is limited by the lack of a centralized clinical registry of patients with rare genetic diseases. However, extrapolating the numbers in the Indian scenario, the Foundation for Research on Rare Diseases and Disorders has estimated that about 70 million people are affected by rare diseases [92]. Rare diseases that have gained attention in the country include blood disorders, lysosomal storage diseases, primary immunodeficiency diseases, mitochondrial diseases, neurodegenerative diseases, and musculoskeletal diseases, among many others [89, 93]. A compilation of estimated prevalence/incidence of well-studied rare diseases in India has been included in Table 2.

Table 2 List of rare genetic diseases with estimated prevalence/ incidence in India

Given the estimate of approximately 70 million people living with rare diseases, most of them undiagnosed, rare disease management contributes a huge burden for a developing country like India. The accurate socio-economic burden due to rare genetic diseases in India is unknown. Incidentally, the social impacts of hemophilia have been recorded adequately, in spite of an underestimated prevalence due to lower case reporting [94]. Other studies have shown that government interventions can reduce the out-of-pocket expenditure of patients [101, 102]. A recent study showed a yearly expenditure of transfusion-dependent thalassemics attending a tertiary care center in India, to be Rs. 41,514 to 1,51,800. This is equivalent to USD 629–2300 with an average of Rs. 74,948 (USD 1135), amounting to almost 40% of the annual income of an Indian family [103]. In recent years, several initiatives have been taken by Indian organizations, both government and non-government, to address rare diseases and the availability of orphan drugs to help ailing patients [104]. However, there are several challenges including physician training, availability of molecular diagnosis, standard treatment protocols, and availability of drugs, among others, that need to be addressed to reduce the rare disease burden in India.

Population scale initiatives for addressing rare diseases in India

Despite over 70 million individuals being affected by rare diseases, India has limited resources committed to treating or understanding rare diseases. In recent years, Indian Council of Medical Research (ICMR) has taken a step towards bridging the gap between patients suffering from rare genetic diseases and healthcare providers by launching The Indian Rare Disease Registry. The registry acts as a common repository for data concerning rare disease patients throughout the country [105]. Furthermore, there are examples of how various organizations, both government and non-government, have developed programs for addressing the rare disease challenge in India. However, most of these efforts are towards specific diseases areas or are targeted to a certain sub-population. Some of the notable initiatives that cater to heterogeneous rare disease patients are highlighted in this section.

Molecular Diagnostics, Counselling, Care and Research Centre (MDCRC) is a not-for-profit charitable organization which takes a holistic approach to manage Duchenne Muscular Dystrophy (DMD) patients, mostly catering to individuals from the southern part of India (Tamil Nadu). MDCRC undertakes genetic counseling in addition to providing screening for DMD and Spinal Muscular Atrophy (SMA). A pilot study by MDCRC estimated the prevalence of DMD to be 2.4 times higher as compared to global estimates [97]. The Uttar Pradesh state government had taken the commendable initiative in the year 2009 by providing anti-hemophilic factors (AHF) free of cost at various centers in the state [106], while the Maharashtra state government has provided clotting factor concentrates (CFC) to the poor sections and emergency cases since 2012 [107]. According to the hemophilia federation of India, 69% of the country is covered by AHF support [108]. These have been successful initiatives for public health in specific rare disease settings. Institute of Medical Genetics and Genomics at the Sri Ganga Ram Hospital, Delhi provides a battery of tests for several rare diseases [109] including blood disorders, metabolic disorders, muscular dystrophies, and Down syndrome [110], among others.

Sanofi-Genzyme’s India Charitable Access Program (INCAP), Shire HGT's charitable access program in partnership with Direct Relief (a non-governmental organization), and Protalix Biotherapeutics have provided access to enzyme replacement therapy for lysosomal storage diseases in India [111]. Apart from these, there are a handful of commercial companies in India that offer genetic testing for rare genetic diseases, thus aiding the rare disease diagnosis requirements. In recent years, ORDI, a non-profit non-government organization in India, is providing a platform for individual rare diseases support groups to come together. They aim to set up patient registries and work with the government to create policies that are orphan disease centered. ORDI undertakes both Indian and global initiatives, and works together with at least 15 rare disease foundations/centers [90].

The Genomics for Understanding Rare Diseases: India Alliance Network (GUaRDIAN) at CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Delhi is a unique research initiative in India that uses the power of genomics to solve and understand rare diseases. Details about the GUaRDIAN program are elaborated in the next section. Apart from those listed above, several government research laboratories, hospitals, and not-for-profit organizations also provide specialized tests for a specific patient group or community (see Tables 3 and 4 for more details).

Table 3 List of major research centers working on rare diseases in India
Table 4 A comprehensive list of rare disease organizations and resources that provide patient support [modified from [90]]


Completion of the human genome project and the availability of the human genome reference sequence have opened up opportunities for a new era of genomic medicine. This has a tremendous impact on diagnosis, treatment, and preventive care related to genetic diseases [112,113,114]. The decade after the completion of the human genome sequence has ushered in significant technological advancements [115,116,117]. These technologies, popularly known as Next Generation Sequencing (NGS) technologies have enabled fast sequencing of genomes at an affordable cost [118, 119]. The improvements in technology have also contributed immensely to the development of complementary methods towards extraction of biological interactions between biomolecules including the transcriptome [120,121,122] and epigenome [123]. In addition, the integration of personal omics data provides opportunities to view the temporal dynamics of omics profiles in an individual [124, 125]. These advances have brought in a paradigm shift in current practices of medicine. Genome sequencing has significantly impacted the understanding of genetic variants and their association with diseases. Recently, exome and genome sequencing are increasingly being used to investigate the genetic bases of diseases including both monogenic as well as complex diseases such as cancer. One of the major applications of such genomic technologies in the clinical setting is the identification and annotation of variants associated with rare genetic diseases [126,127,128,129,130]. A rare disease patient usually undergoes three misdiagnoses and takes up to 7 years to reach the right diagnosis [131]. With genome sequencing technologies, it is now possible to look at either the entire genome or the protein-coding regions (exomes) that may harbor deleterious variations, in a reasonable time. Given the presence of unique variations in Indian populations, absent elsewhere in the world, genomics-based solutions are the way forward to tackle the high burden of rare diseases. Identifying the causative variant(s) in rare genetic diseases would be important not only in enabling accurate diagnosis but also in counseling and genetic screening applications.

The major challenges in realizing the full potential of genomics technologies for identifying genetic disease-causing variants in India are manifold. These include the uniqueness of the Indian genetic pool, lack of a program for identifying rare genetic diseases, and a comprehensive registry of rare genetic diseases, logistics of sample procurement and processing, common protocols for genome sequencing and computational analysis, and methodologies for validating the functionality of the reported variation(s). Genomics for Understanding Rare Diseases: India Alliance Network (GUaRDIAN) is a research consortium which was proposed to address the above challenges. The consortium includes clinicians, clinical geneticists, genomics scientists, computational analysts, and basic research biologists, among others. The clinicians and clinical geneticists form the primary contacts and act as caregivers for the patients. The geneticists, genomics scientists, and researchers provide the necessary expertise required to identify the genetic variations, create models for understanding disease mechanisms, and explore the therapeutic potential of small molecules for rare genetic diseases. The simplified workflow of the GUaRDIAN consortium is summarized in Fig. 1. The GUaRDIAN is an open-ended consortium of individuals, who are actively invited to join the consortium, with an agreement to follow the general principles and framework, and the data access policies. A common framework for the exchange of datasets, resources within the consortium, and participatory approach has been proposed to realize the full potential of clinical genomics.

Fig. 1

The GUaRDIAN framework. Clinicians refer patients and family members to GUaRDIAN consortium following which the blood/DNA samples and complete clinical investigations are shared. The samples undergo next generation sequencing, bioinformatic analyses, and variant prediction. The predicted genetic variant is checked for segregation in the family members using capillary sequencing. If a known pathogenic variant is identified, a research report is generated and sent back to the clinician. When a putative novel variant is identified, the effect of the genetic variant is modeled in a suitable system to validate the functionality of the variant and also to understand the disease mechanism. Further, the genetic variant information derived from patient/family is made available for community-level screening

The aim of the GUaRDIAN consortium is to establish a unique collaborative framework in health care planning, implementation, and delivery in the specific area of rare genetic diseases. The consortium proposes to apply the power of genomics for systematic characterization and diagnosis of rare genetic diseases in India. The GUaRDIAN network is connected to hospitals and major tertiary care centers across India. The consortium currently encompasses over 240 clinicians/researchers, from 70 clinical/research centers across India [132]. The GUaRDIAN is a research program and not a clinical service.

GUaRDIAN ethical framework

A strong foundation of an ethical and legal framework is necessary for seamless collaboration and sharing of genetic data across the boundaries of institutions. The GUaRDIAN consortium is strongly anchored on the basic principles of beneficence, reciprocity, justice, and professional responsibility. As part of the collaborators’ network, a common format for collection of clinical and genetic data has been created. Additional efforts have gone into standardizing the patient information. The benefits and potential ethical, legal, and social implications of whole exome or genome sequencing and availability of the anonymized data in the public domain are conveyed in detail to the patients and family. The identity stripped clinically annotated data of variations is available to all the members through a firewalled access. In addition, publications in peer-reviewed journals serve as the major interaction points for sharing findings with the general clinical and research community.

GUaRDIAN clinical registry

As part of the collaborative initiative, a referral system for systematic collection and curation of baseline data is being maintained. The program collects detailed clinical information, including the signs, symptoms, and clinical investigations performed on the patient and family members. The GUaRDIAN maintains a semantically oriented framework, which relies extensively on the internationally accepted and popularly used semantic ontologies established and widely used including the human phenotype ontology [133]. The application of such a centralized data resource is manifold. While on the one end, it not only provides a holistic view of the burden of genetic diseases in the country, it also provides immense insights into the common and rare genetic variants in different sub-populations. This would enable clinicians and policy-makers to design intervention programs including genetic education and genetic counseling.

GUaRDIAN sequence data generation

A centralized sequencing facility has been established at the CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Delhi, which can be accessed by any collaborator in order to generate high-quality NGS sequencing data as per international standards [134,135,136], with various platforms such as Hiseq 2500 and NovaSeq 6000 (Illumina Inc. USA). A dedicated training team for both experimental and computational work necessary to perform the data capture and analysis of high-throughput sequencing data is also channelized as a part of the GUaRDIAN consortium. Investigators are free to generate sequence data on their own or from other commercial facilities that adhere to international guidelines and GUaRDIAN consortium standards. The sequencing requirements are updated and modified in accordance with the technological advancement and emerging international consensus.

GUaRDIAN data analysis, integration, interpretation, and sharing

GUaRDIAN stands for providing scientifically sound and clinically actionable solutions. The genomes/exomes of patients are analyzed through custom built in-house bioinformatic pipelines to identify the most accurate genetic variation that can explain a certain condition. Further, the pathogenicity of variants is predicted by the latest guidelines laid down by the American College of Medical Genetics and Genomics [136]. The GUaRDIAN consortium relies heavily on datasets, tools, and resources developed across the whole world, including methods and tools developed as part of the OpenPGx consortium [137, 138]. The consortium depends on open source architectures, tools, and open access resources, to enable easy replication, scalability, and future implementation in independent clinical setups.

Data sharing also forms a major component of the program and collaboration. The anonymized clinically annotated data of variations is available to all members through a firewalled access. In addition, the summary data of each novel variant and/or allele frequencies would be available in the public domain without access restrictions. Credits for contributions are a major point to address in such a scalable collaborative network. All collaborating members of the network shall agree to adhere to basic principles of data veracity and ethical codes of conduct. The credit-sharing agreement forms the major framework of trust between participating members. This shall be in line with principles laid out for biomedical resource contributions [139].

GUaRDIAN reporting, community screening, and disease modeling

Once the GUaRDIAN computational analysis identifies a pathogenic variation of clinical significance, it is subjected to validation by segregation analysis. After this, if the identified genetic variation is immediately actionable, the information is transferred to the clinician as a research report which will be used for patient counseling. This genetic information can further be used for making informed decisions by the family. Wherever required, the genetic variation information is utilized for potential community-level screening programs, thus building towards affordable diagnostic solutions.

In the case where novel pathogenic variations are identified, researchers at the GUaRDIAN consortium replicate the disease in suitable models such as zebrafish and patient-derived IPSCs to gain the correlation between the disease phenotype and the identified variant. Genetic engineering to create disease models also provides the opportunity for discovery of novel therapeutics as well as to repurpose existing drugs for new indications in rare genetic diseases.

GUaRDIAN success stories

A large number of cases have been solved through the GUaRDIAN program, and a subset of interesting investigations have been published in peer-reviewed journals, which encompass diseases as diverse as epidermolysis bullosa [140,141,142,143], familial Mediterranean fever [144], lamellar ichthyosis [145], sporadic acrokeratosis verruciformis [146], rare syndromes of mineralocorticoid excess [147], severe combined immunodeficiency [148], X-linked agammaglobulinemia [149], hyper IgE syndrome [150], Dowling-Degos disease [151], and megalencephalic leukoencephalopathy [152], to list a few. Furthermore, GUaRDIAN is actively investigating the genetic conundrum in Indian rare disease cohorts conforming to cardiology, neurology, dermatology, primary immunodeficiency, endocrinology, nephrology, mitochondrial disorders, and lysosomal storage disorders, among others.

Of the many success stories of GUaRDIAN, the diagnosis of a rare mutation in megalencephalic leukoencephalopathy with subcortical cysts 1 (MLC1) gene in leukodystrophy was instrumental in community service in the form of affordable diagnostics. Six children from a consanguineous Muslim family belonging to the Nalband community from north India were presented with difficulty in balancing the head and inability to sit independently, with recurrent episodes of seizures. Based on the clinical characteristics, the provisional diagnosis of leukodystrophy was made; however, leukodystrophies are a class of disorders with the involvement of multiple genes. Whole exome sequencing revealed a homozygous variation in the MLC1 gene, found to be segregated among all the affected members and was absent in all the unaffected members. Based on this, the diagnosis of megalencephalic leukoencephalopathy with subcortical cysts (MLC) was confirmed. MLC is a rare leukodystrophy characterized by macrocephaly, progressive motor dysfunction, recurrent episodes of seizures, and mental retardation. Further, three more families from the same community were found to be affected and carried the same variation, indicating a founder effect. As a follow up for this, an additional 83 members of the community were screened. Out of these, 24 were found to be the carriers and 9 were affected [152]. The Nalband community consists of over 5000 members scattered across north India as well as Pakistan. Like many other communities in India, consanguineous marriages are common in the Nalband community. In order to aid the entire community, a polymerase chain reaction (PCR)-based assay for the Nalband mutation in MLC1 has been developed for carrier status determination and prenatal screening, at an affordable cost.

Another area where the GUaRDIAN has made a significant contribution is in the rare diseases of the skin. Epidermolysis bullosa (EB), a skin-blistering disease, was once considered ultra-rare in the Indian population. Epidermolysis bullosa simplex (EBS) is the most common subtype of EB. The GUaRDIAN team identified a novel variant in the Keratin 5 (KRT5) gene in a large multigenerational family from northwestern India. The variant was shown to be segregated in nine affected members in the family but found absent in five unaffected members. The study reported the first causative mutation for EBS from India [140]. Whole exome sequencing has also enabled the detection of a novel homozygous nonsense variant in Keratin 14 (KRT14) gene in an autosomal recessive form of EB, in two siblings presented with generalized blistering of the skin and dystrophic nails. The same study identified a known homozygous stop gain variant in the same gene in a child with trauma-induced blistering all over the body [153]. In cases of junctional epidermolysis bullosa (JEB) and dystrophic epidermolysis bullosa (DEB), the phenotype and genotype spectrum of the disease was described for the first time from India through collaborative efforts of GUaRDIAN. JEB was studied in a small cohort of six patients from four consanguineous families with a wide range of clinical variability, identifying variations in the genes laminin subunit alpha 3 (LAMA3), laminin subunit β3 (LAMB3), collagen type XVII α1 (COL17A1) [142]. In the case of DEB, 18 patients from 17 unrelated families were studied and 20 distinct variations were found in COL7A1 gene [143]. There have also been other reports which discovered novel variants that expanded the known mutation spectrum of EB [141, 154].

GUaRDIAN has contributed to the identification of the pharmacogenetic variants in dihydropyrimidine dehydrogenase (DPYD) gene, which determines the metabolism of the commonly used anti-neoplastic drug 5-fluorouracil, in south-east Asian countries [155]. The consortium has also undertaken international initiatives to derive the pharmacogenomic landscape in Malays [156] and Qatari populations [157, 158], and to identify genetic variants of Arab, Middle East, and North African populations [159, 160]. GUaRDIAN has also set up a systematic pipeline for next generation sequencing of the mitochondrial genome for clinical applications, called the mit-o-matic [80].

In the era of clinical genomics, it is imperative for clinicians to be well equipped with the basics of high-throughput data analysis so as to interpret the data concerning a certain disease. Keeping this in mind, the GUaRDIAN consortium initiated an outreach program, where clinicians are trained in basics of NGS technologies and systematic computational analysis of sequencing data as a part of continuing medical education (CME) workshops. A handbook called ‘Exome Sequence Analysis and Interpretation for Clinicians’ has been prepared and made available for free download from Google Books [161]. Over 8000 soft copies of the book have been downloaded and over 800 print copies have been distributed to clinicians in meetings and CMEs (as of January 2019). More than 500 clinicians have been trained across the country. The GUaRDIAN outreach program is a small step towards providing health and economic benefits to families with rare genetic diseases.

Impact of genomics in diagnosis of rare genetic diseases in India

It has been increasingly shown that the challenges of genetic and phenotypic heterogeneity which makes diagnosis of rare genetic diseases cumbersome could potentially be addressed by using next generation sequencing techniques, enabling the high-throughput identification and annotation of causal variants [126, 129, 162, 163]. In the present scenario, the rare diseases which require immediate attention in India are primary immunodeficiencies, hemoglobinopathies, muscular dystrophies, metabolic disorders, and neurological disorders, among others. The earlier section described the contributions made by a genomics-enabled nation-wide network, GUaRDIAN. There have also been other individual genomics-based studies that have aided in addressing rare diseases.

In the case of Duchenne muscular dystrophy (DMD), a wide spectrum of mutations and frequencies have been shown in patients from different Indian sub-populations [164,165,166]. The dystrophin gene spans over 2000 kb at the DNA level, with pathogenic variations identified within introns as well. Traditional methods based on multiplex ligation-dependent probe amplification (MLPA) have been used to detect carrier status in DMD [167,168,169,170]. A recent study showed that NGS can be used in the diagnosis of muscular dystrophies in MLPA negative cases with a success rate of as high as 100% [171].

Lysosomal storage disorders (LSD), a class of more than 50 genetic diseases, are found to be of high burden in India [172]. The overlapping phenotypes and involvement of multiple genes in lysosomal disorders, and the need for intervention in the form of enzyme replacement therapy at the earliest, call for use of NGS approaches for faster diagnosis. In Niemann–Pick disease type C, an LSD with a wide clinical spectrum, a novel mutation was identified by whole exome sequencing in a proband of Asian origin, which was a deletion spanning two exons of Niemann–Pick disease type C2 (NPC2) gene [173].

An estimated one million Indians are affected by primary immunodeficiencies, a class comprising of hundreds of genetic disorders [174]. The utmost challenging facet of PIDs is under diagnosis, owing to the high incidence of infectious diseases in countries like India [175]. Whole exome sequencing approach has proved to be instrumental in identifying mutations in capillary sequencing negative cases of X-linked agammaglobulinemia (XLA) [149], severe combined immunodeficiency (SCID) [148], B cell expansion with NF-κB, and T cell anergy (BENTA) [176], apart from targeted next generation sequencing in SCID [177] and major histocompatibility complex class II deficiency [178].

Mitochondrial disorders are difficult to diagnose owing to overlapping phenotypes and multi-system involvement. Whole mitochondrial genome sequencing coupled with nuclear gene sequencing has been performed to establish genotype-phenotype correlations in a cohort of patients from South India [179]. Whole exome sequencing has incidentally helped in diagnosing mitochondrial diseases due to nuclear genome variations [180, 181].

In case of autosomal recessive forms of ataxia, such as spastic ataxia [182] and cerebellar ataxias [183], homozygosity mapping as well as whole exome sequencing has played a major role in discovering the novel variants in Indian patients. Application of genomic diagnosis has been appreciated for skeletal dysplasias in a recent study. The study on a large cohort using capillary sequencing as well as NGS has added novel variants to the existing literature [184]. Exome sequencing also has been used to discover novel mutations in multiple joint dislocation syndrome [185], Schwartz-Jampel syndrome type 1 [186], and progressive pseudorheumatoid dysplasia [187]. Currently, a limited number of clinicians are using NGS-based diagnosis of rare genetic diseases in India but this number is increasing at a rapid pace. With several success stories emerging from India, genomics will become a mainstay for diagnosis of rare genetic diseases in the near future.

Translating genomics to affordable diagnostics for rare genetic diseases

Although the cost of next generation sequencing-based diagnostics is declining, with more than 70 million people suffering from a genetic disease in India, affordable and faster measures are required to cater to the needs of the ailing population. CSIR-IGIB has an ongoing outreach platform to provide affordable access to genetic testing for common genetic diseases. The program named “Genomics and other Omics tools for Enabling Medical Decision (GOMED)” [188] provides molecular genetic assays for clinical diagnosis, prenatal testing, and carrier screening. In this ‘from bench to bedside’ model, a battery of low-cost genetic diagnostic assays for diseases pertaining to neurology, cardiology, and many other disorders are available. Till now, over 90 candidate gene tests and 7 comprehensive gene panel tests have been developed by GOMED. Over 20,000 molecular tests for about 6000 patients have been performed across the country (As of 2018). This clinical service is provided free of cost to needy patients. GOMED has been particularly beneficial in the community screening of sub-population-specific mutations. Whole exome sequencing had revealed a founder mutation in MLC1 gene in individuals from Nalband community suffering from megalencephalic leukoencephalopathy with subcortical cysts (MLC) [152]. As part of GOMED, a low-cost diagnostic assay was developed to screen for carriers in other members of this community comprising of 5000 people scattered across different regions in north India. Spinocerebellar ataxia (SCA) type 3, known as Machado–Joseph disease (MJD) is one of the most common ataxias globally, while presenting rarely in India. Intervention by CSIR-IGIB revealed the hidden burden of SCA3/MJD in 100–200 families in a close-knit community in Maharashtra. This information is now available as an assay under GOMED. GOMED also expands to pharmacogenetic testing to prevent adverse reactions to commonly used drugs such as the anticancer drug 5-fluorouracil. 5-fluorouracil (5-FU) is an anti-neoplastic drug which is administered in a number of cancers, the clearance of which is mediated by a rate-limiting enzyme dihydropyrimidine dehydrogenase (DPYD). Genotyping of four variants in DPYD gene that were found to be associated with 5-FU toxicity in South Asian population [155] has been made available as an affordable diagnostic assay for testing cancer patients before administering the drug to prevent adverse reactions. The GOMED program also actively works with commercial diagnostic companies to provide technologies for the affordable diagnosis of common and rare genetic diseases in India.

As a step towards improving public health, efforts have also been undertaken to compile a directory of genetic test services and counseling centers in India. The directory includes about 120 centers across various states in India. It acts as a resource for clinicians as well as researchers for referring to facilities which provide accessible and comprehensive public healthcare [189].

The way ahead

There are a few priority areas that are emerging in the country as far as rare diseases are concerned. Newborn screening at a nation-wide level is pivotal in reducing the burden of rare diseases. In 2014, India Newborn Action Plan (INAP) was released to reduce the incidence of child birth defects and stillbirths [190]. While at present, there are limitations in implementing genomics-based diagnosis at population scale [191], Indian pediatricians are hopeful about the genomic interventions and resultant advancements in diagnosis, especially for non-invasive prenatal testing [192]. National Policy for Treatment of Rare Diseases was released by the Indian Ministry of Health and Family Welfare in 2017 [193]. However, this policy was withdrawn in November 2018 to the utter dismay of the patients and family members suffering from rare diseases [194]. As personal genome-sequencing becomes popular, it is important to create a policy and a legal framework for non-discrimination of individuals based on the genetic information. This would be in line with the Genetic Information Nondiscrimination Act (GINA) of the USA but also adapted to the social and cultural sensibilities specific to India. As we look ahead, we should involve stakeholders such as government policy-makers, research scientists, clinicians, hospitals, patient groups, and non-governmental organizations to join forces to find meaningful solutions for rare diseases patients.

For a large and heterogeneous population like that of India, it has been shown that the international genomics initiatives such as the 1000 genome project have an inadequate representation of the genetic diversity due to limited sampling [20]. In highly endogamous populations such as the Ashkenazi Jewish population, genomics has been crucial in understanding rare diseases with founder effects [195]. With an enormous and stratified population, practicing extensive endogamy [39], it is expected that India would have a high prevalence of rare genetic diseases. Therefore, it is essential to know the causal genes and pathogenic genetic variants and the sub-populations where they are prevalent, to aid in the appropriate and cost-effective diagnosis of rare diseases. There are several initiatives in India that are attempting to address this space by building large-scale whole genome datasets of the representative population. Programs such as the GenomeAsia100K, which has representative samples from India, seek to sequence and analyze individuals to help enable medical applications [196]. The Government of India has announced a Bioscience Mission for Precision Health and Optimal Well-being, which will involve large-scale human genome sequencing across India [197]. Towards this, the Council of Scientific and Industrial Research (CSIR), India, has also initiated a whole genome sequencing program titled “Genomics for Public Health (IndiGen)” [198] to help accelerate biomedical applications in India. These population scale genomics programs will definitely provide the momentum and ecosystem for driving rare disease genomics in India.


India is home to culturally and genetically diverse populations, which are burdened by genetic diseases. Due to the high prevalence of recessive alleles owing to endogamous practices, rare diseases form a significant burden in India. Genomics can greatly aid in addressing rare disease burden by faster and more accurate diagnoses. The Genomics for Understanding Rare Diseases: India Alliance Network (GUaRDIAN) provides a template for a nation-wide collaborative platform that uses the power of genomics to dissect the rare disease conundrum. More such pan-India genomics-driven initiatives can help in deriving Indian-specific references for deducing pathogenic and benign variations in the population, which can pave the way for precision medicine, including in the rare disease space.

Availability of data and materials

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.





Anti-hemophilic factors


B cell expansion with NF-κB and T cell anergy


Clotting factor concentrates


Continuing medical education


Collagen type XVII α1


Council of Scientific and Industrial Research


Dystrophic Epidermolysis Bullosa


Duchenne Muscular Dystrophy


Dihydropyrimidine dehydrogenase


Epidermolysis bullosa


Epidermolysis bullosa simplex


Genomics and other Omics tools for Enabling Medical Decision


Genomics for Understanding Rare Diseases: India Alliance Network


Indian Council of Medical Research


Indian Genetic Disease Database


Institute of Genomics and Integrative Biology


Indian Genome Variation


India Newborn Action Plan


India Charitable Access Program


INDian EXome database


Junctional Epidermolysis Bullosa




Laminin subunit α3


Laminin subunit β3


Lysosomal storage disorders


Molecular Diagnostics, Counseling, Care and Research Centre


Machado Joseph Disease


Megalencephalic Leukoencephalopathy with subcortical Cysts


Multiplex ligation-dependent probe amplification


Next generation sequencing


Niemann-Pick disease type C2


Organization for Rare Diseases India


Polymerase chain reaction


South Asian Genomes and Exomes


Spinocerebellar ataxia


Severe combined immunodeficiency


Spinal muscular atrophy


Single nucleotide polymorphism


X-linked agammaglobulinemia


  1. 1.

    Reich D, Thangaraj K, Patterson N, Price AL, Singh L. Reconstructing Indian population history. Nature. 2009;461(7263):489–94.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  2. 2.

    Majumder PP, Basu A. A genomic view of the peopling and population structure of India. Cold Spring Harb Perspect Biol. 2014;7(4):a008540.

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Basu A, Sarkar-Roy N, Majumder PP. Genomic reconstruction of the history of extant populations of India reveals five distinct ancestral components and a complex structure. Proc Natl Acad Sci U S A. 2016;113(6):1594–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    Narasimhan AVM, Patterson N, Moorjani P, Lazaridis I. The Genomic Formation of South and Central Asia. 2018.

  5. 5.

    Singh KS. People of India: Introduction. Delhi: Oxford University Press; 2002.

  6. 6.

    Bamshad M, Kivisild T, Watkins WS, Dixon ME, Ricker CE, Rao BB, et al. Genetic evidence on the origins of Indian caste populations. Genome Res. 2001;11(6):994–1004.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Malhotra KC. Morphological composition of the people of India. J Hum Evol. 1978;7(1):45–53.

    Article  Google Scholar 

  8. 8.

    Kivisild T, Rootsi S, Metspalu M, Mastana S, Kaldma K, Parik J, et al. The genetic heritage of the earliest settlers persists both in Indian tribal and caste populations. Am J Hum Genet. 2003;72(2):313–32.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  9. 9.

    Cavalli-Sforza LL, Menozzi P, Piazza A. The History and Geography of Human Genes: Abridged paperback Edition. Princeton: Princeton University Press; 2018.

  10. 10.

    Indian Genome Variation Consortium. The Indian Genome Variation database (IGVdb): a project overview. Hum Genet. 2005;118(1):1–11.

    Article  CAS  Google Scholar 

  11. 11.

    Das K, Malhotra KC, Mukherjee BN, Walter H, Majumder PP, Papiha SS. Population structure and genetic differentiation among 16 tribal populations of Central India. Hum Biol. 1996;68(5):679–705.

    CAS  PubMed  Google Scholar 

  12. 12.

    Majumder PP, Roy B, Banerjee S, Chakraborty M, Dey B, Mukherjee N, et al. Human-specific insertion/deletion polymorphisms in Indian populations and their possible evolutionary implications. Eur J Hum Genet. 1999;7(4):435–46.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Thanseem I, Thangaraj K, Chaubey G, Singh VK, Bhaskar LVKS, Reddy BM, et al. Genetic affinities among the lower castes and tribal groups of India: inference from Y chromosome and mitochondrial DNA. BMC Genet. 2006;7:42.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  14. 14.

    Khan F, Pandey AK, Borkar M, Tripathi M, Talwar S, Bisen PS, et al. Effect of sociocultural cleavage on genetic differentiation: a study from North India. Hum Biol. 2008;80(3):271–86.

    PubMed  Article  Google Scholar 

  15. 15.

    Borkar M, Ahmad F, Khan F, Agrawal S. Paleolithic spread of Y-chromosomal lineage of tribes in eastern and northeastern India. Ann Hum Biol. 2011;38(6):736–46.

    PubMed  Article  Google Scholar 

  16. 16.

    Guha P, Das A, Dutta S, Bhattacharjee S, Chaudhuri TK. Study of genetic diversity of KIR and TLR in the Rabhas, an endogamous primitive tribe of India. Hum Immunol. 2015;76(11):789–94.

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Chinniah R, Vijayan M, Thirunavukkarasu M, Mani D, Raju K, Ravi PM, et al. Polymorphic Alu insertion/deletion in different caste and tribal populations from South India. PLoS One. 2016;11(6):e0157468.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  18. 18.

    Vadivelu MK. Emergence of sociocultural norms restricting intermarriage in large social strata (endogamy) coincides with foreign invasions of India. Proc Natl Acad Sci USA. 2016;113(16):E2215–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  19. 19.

    Bhasin MK, Nag S. Consanguinity and its effects on fertility, mortality and morbidity in the Indian Region: A Review. Int J Hum Genet. 2012;12(4):197–301.

    Article  Google Scholar 

  20. 20.

    Sengupta D, Choudhury A, Basu A, Ramsay M. Population stratification and underrepresentation of Indian subcontinent genetic diversity in the 1000 genomes project dataset. Genome Biol Evol. 2016;8(11):3460–70.

    PubMed  PubMed Central  Article  Google Scholar 

  21. 21.

    Indian Genome Variation Consortium. Genetic landscape of the people of India: a canvas for disease gene exploration. J Genet. 2008;87(1):3–20.

    Article  Google Scholar 

  22. 22.

    Narang A, Das RR, Chaurasia A, Mukhopadhyay A, Mukerji M, Dash D. IGVBrowser--a genomic variation resource from diverse Indian populations. Database (Oxford). 2010;2010:baq022.

    Article  Google Scholar 

  23. 23.

    Sinha S, Mishra SK, Sharma S, Patibandla PK, Mallick PK, Sharma SK, et al. Polymorphisms of TNF-enhancer and gene for FcgammaRIIa correlate with the severity of falciparum malaria in the ethnically diverse Indian population. Malar J. 2008;7:13.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  24. 24.

    Sinha S, Qidwai T, Kanchan K, Anand P, Jha GN, Pati SS, et al. Variations in host genes encoding adhesion molecules and susceptibility to falciparum malaria in India. Malar J. 2008;7:250.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  25. 25.

    Sinha S, Arya V, Agarwal S, Habib S. Genetic differentiation of populations residing in areas of high malaria endemicity in India. J Genet. 2009;88(1):77–80.

    PubMed  Article  Google Scholar 

  26. 26.

    Jha P, Sinha S, Kanchan K, Qidwai T, Narang A, Singh PK, et al. Deletion of the APOBEC3B gene strongly impacts susceptibility to falciparum malaria. Infect Genet Evol. 2012;12(1):142–8.

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Kanchan K, Pati SS, Mohanty S, Mishra SK, Sharma SK, Awasthi S, et al. Polymorphisms in host genes encoding NOSII, C-reactive protein, and adhesion molecules thrombospondin and E-selectin are risk factors for Plasmodium falciparum malaria in India. Eur J Clin Microbiol Infect Dis. 2015;34(10):2029–39.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Bhattacharjee A, Banerjee D, Mookherjee S, Acharya M, Banerjee A, Ray A, et al. Leu432Val polymorphism in CYP1B1 as a susceptible factor towards predisposition to primary open-angle glaucoma. Mol Vis. 2008;14:841–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Kumar J, Garg G, Kumar A, Sundaramoorthy E, Sanapala KR, Ghosh S, et al. Single nucleotide polymorphisms in homocysteine metabolism pathway genes: association of CHDH A119C and MTHFR C677T with hyperhomocysteinemia. Circ Cardiovasc Genet. 2009;2(6):599–606.

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Aggarwal S, Negi S, Jha P, Singh PK, Stobdan T, Pasha MAQ, et al. EGLN1 involvement in high-altitude adaptation revealed through genetic analysis of extreme constitution types defined in Ayurveda. Proc Natl Acad Sci U S A. 2010;107(44):18961–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  31. 31.

    Aggarwal S, Gheware A, Agrawal A, Ghosh S, Prasher B, Mukerji M. Combined genetic effects of EGLN1 and VWF modulate thrombotic outcome in hypoxia revealed by Ayurgenomics approach. J Transl Med. 2015;13:184.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  32. 32.

    Biswas A, Maulik M, Das SK, Ray K, Ray J. Parkin polymorphisms: risk for Parkinson’s disease in Indian population. Clinical genetics. Denmark. 2007;72:484–6.

    CAS  Article  Google Scholar 

  33. 33.

    Biswas A, Sadhukhan T, Majumder S, Misra AK, Das SK, Variation Consortium IG, et al. Evaluation of PINK1 variants in Indian Parkinson’s disease patients. Parkinsonism Relat Disord. 2010;16(3):167–71.

    PubMed  Article  Google Scholar 

  34. 34.

    Gupta A, Maulik M, Nasipuri P, Chattopadhyay I, Das SK, Gangopadhyay PK, et al. Molecular diagnosis of Wilson disease using prevalent mutations and informative single-nucleotide polymorphism markers. Clin Chem. 2007;53(9):1601–8.

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Chaki M, Sengupta M, Mondal M, Bhattacharya A, Mallick S, Bhadra R, et al. Molecular and functional studies of tyrosinase variants among Indian oculocutaneous albinism type 1 patients. J Invest Dermatol. 2011;131:260–2.

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    Grover S, Gourie-Devi M, Baghel R, Sharma S, Bala K, Gupta M, et al. Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics. 2010;11(7):927–41.

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Talwar P, Kanojia N, Mahendru S, Baghel R, Grover S, Arora G, et al. Genetic contribution of CYP1A1 variant on treatment outcome in epilepsy patients: a functional and interethnic perspective. Pharmacogenomics J. 2017;17(3):242–51.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Giri AK, Khan NM, Grover S, Kaur I, Basu A, Tandon N, et al. Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population. Pharmacogenomics. 2014;15(10):1337–54.

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Nakatsuka N, Moorjani P, Rai N, Sarkar B, Tandon A, Patterson N, et al. The promise of discovering population-specific disease-associated genes in South Asia. Nat Genet. 2017;49(9):1403–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  40. 40.

    Christianson A, Howson CP, Modell B. March Of Dimes Global Report On Birth Defects. 2006. Available from: Accessed 28 Mar 2019.

    Google Scholar 

  41. 41.

    Kaur A, Singh JR. Chromosomal abnormalities: genetic disease burden in India. Int J Hum Genet. 2010;10(1–3):1–14.

    Google Scholar 

  42. 42.

    Singh I, Faruq M, Mukherjee O, Jain S, Pal PK, Srivastav MVP, et al. North and South Indian populations share a common ancestral origin of Friedreich’s ataxia but vary in age of GAA repeat expansion. Ann Hum Genet. 2010;74(3):202–10.

    PubMed  Article  CAS  Google Scholar 

  43. 43.

    Sachdeva K, Saxena R, Puri R, Bijarnia S, Kohli S, Verma IC. Mutation analysis of the CFTR gene in 225 children: identification of five novel severe and seven reported severe mutations. Genet Test Mol Biomarkers. 2012;16(7):798–801.

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Venugopal A, Chandran M, Eruppakotte N, Kizhakkillach S, Breezevilla SC, Vellingiri B. Monogenic diseases in India. Mutat Res. 2018;776:23–31.

    CAS  PubMed  Article  Google Scholar 

  45. 45.

    Verma IC, Bijarnia-Mahay S, Jhingan G, Verma J. Newborn screening: need of the hour in India. Indian J Pediatr. 2015;82(1):61–70.

    PubMed  Article  Google Scholar 

  46. 46.

    Kabra M. Dietary management of inborn errors of metabolism. Indian J Pediatr. 2002;69(5):421–6.

    PubMed  Article  Google Scholar 

  47. 47.

    Sachdeva A. Dietary interventions for rare metabolic disorders—now available in India! Indian Pediatr. 2017;54(11):909–10.

    PubMed  Article  Google Scholar 

  48. 48.

    Mohanty D, Colah RB, Gorakshakar AC, Patel RZ, Master DC, Mahanta J, et al. Prevalence of beta-thalassemia and other haemoglobinopathies in six cities in India: a multicentre study. J Community Genet. 2013;4(1):33–42.

    CAS  PubMed  Article  Google Scholar 

  49. 49.

    Nadkarni AH, Gorakshakar AC, Sawant PM, Italia KY, Upadhye DS, Gorivale MS, et al. The phenotypic and molecular diversity of hemoglobinopathies in India: a review of 15 years at a referral center. Int J Lab Hematol. 2019;41(2):218–26.

    PubMed  Article  Google Scholar 

  50. 50.

    Verma IC, Lall M, Dua PR. Down syndrome in India—diagnosis, screening, and prenatal diagnosis. Clin Lab Med. 2012;32(2):231–48.

    PubMed  Article  Google Scholar 

  51. 51.

    Pradhan S, Sengupta M, Dutta A, Bhattacharyya K, Bag SK, Dutta C, et al. Indian genetic disease database. Nucleic Acids Res. 2011;39(Database issue):D933–8.

    CAS  PubMed  Article  Google Scholar 

  52. 52.

    Indian Genetic Disease Database. Accessed 28 Mar 2019.

  53. 53.

    Mahajan A, Chavali S, Kabra M, Chowdhury MR, Bharadwaj D. Molecular characterization of hemophilia B in North Indian families: identification of novel and recurrent molecular events in the factor IX gene. Haematologica. 2004;89(12):1498–503.

    CAS  PubMed  Google Scholar 

  54. 54.

    Quadros L, Ghosh K, Shetty S. Novel mutations in factor IX gene from western India with reference to their phenotypic and haplotypic attributes. J Pediatr Hematol Oncol. 2009;31(3):157–60.

    CAS  PubMed  Article  Google Scholar 

  55. 55.

    Sharma N, Das R, Kaur J, Ahluwalia J, Trehan A, Bansal D, et al. Evaluation of the genetic basis of phenotypic heterogeneity in north Indian patients with thalassemia major. Eur J Haematol. 2010;84(6):531–7.

    CAS  PubMed  Article  Google Scholar 

  56. 56.

    Dash PM, Sahu PK, Patel S, Mashon RS, Kharat KR, Mukherjee MB. Effect of assorted globin haplotypes and alpha-thalassemia on the clinical heterogeneity of Hb S-beta-thalassemia. Hemoglobin. 2018;42(4):236–42.

    CAS  PubMed  Article  Google Scholar 

  57. 57.

    Hockham C, Bhatt S, Colah R, Mukherjee MB, Penman BS, Gupta S, et al. The spatial epidemiology of sickle-cell anaemia in India. Sci Rep. 2018;8(1):17685.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  58. 58.

    Khan NA, Govindaraj P, Soumittra N, Sharma S, Srilekha S, Ambika S, et al. Leber’s hereditary optic neuropathy-specific mutation m.11778G>A exists on diverse mitochondrial haplogroups in India. Invest Ophthalmol Vis Sci. 2017;58(10):3923–30.

    CAS  PubMed  Article  Google Scholar 

  59. 59.

    Waldmuller S, Sakthivel S, Saadi AV, Selignow C, Rakesh PG, Golubenko M, et al. Novel deletions in MYH7 and MYBPC3 identified in Indian families with familial hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2003;35(6):623–36.

    CAS  PubMed  Article  Google Scholar 

  60. 60.

    Dhandapany PS, Sadayappan S, Xue Y, Powell GT, Rani DS, Nallari P, et al. A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia. Nat Genet. 2009;41(2):187–91.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  61. 61.

    Lakkakula S, Mohan Pathapati R, Chaubey G, Munirajan AK, Lakkakula BV, Maram R. NAT2 genetic variations among South Indian populations. Hum genome Var. 2014;1:14014.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  62. 62.

    Rani DS, Carlus SJ, Poongothai J, Jyothi A, Pavani K, Gupta NJ, et al. CAG repeat variation in the mtDNA polymerase gamma is not associated with oligoasthenozoospermia. Int J Androl. 2009;32(6):647–55.

    CAS  PubMed  Article  Google Scholar 

  63. 63.

    Mehrotra S, Oommen J, Mishra A, Sudharshan M, Tiwary P, Jamieson SE, et al. No evidence for association between SLC11A1 and visceral leishmaniasis in India. BMC Med Genet. 2011;12:71.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  64. 64.

    Giri AK, Khan NM, Basu A, Tandon N, Scaria V, Bharadwaj D. Pharmacogenetic landscape of clopidogrel in north Indians suggest distinct interpopulation differences in allele frequencies. Pharmacogenomics. 2014;15(5):643–53.

    CAS  PubMed  Article  Google Scholar 

  65. 65.

    Gautam P, Jha P, Kumar D, Tyagi S, Varma B, Dash D, et al. Spectrum of large copy number variations in 26 diverse Indian populations: potential involvement in phenotypic diversity. Hum Genet. 2012;131(1):131–43.

    PubMed  Article  Google Scholar 

  66. 66.

    Kitzman JO, Mackenzie AP, Adey A, Hiatt JB, Patwardhan RP, Sudmant PH, et al. Haplotype-resolved genome sequencing of a Gujarati Indian individual. Nat Biotechnol. 2011;29(1):59–63.

    CAS  PubMed  Article  Google Scholar 

  67. 67.

    Patowary A, Purkanti R, Singh M, Chauhan RK, Bhartiya D, Dwivedi OP, et al. Systematic analysis and functional annotation of variations in the genome of an Indian individual. Hum Mutat. 2012;33(7):1133–40.

    CAS  PubMed  Article  Google Scholar 

  68. 68.

    Gupta R, Ratan A, Rajesh C, Chen R, Kim HL, Burhans R, et al. Sequencing and analysis of a South Asian-Indian personal genome. BMC Genomics. 2012;13:440.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  69. 69.

    Wong L-P, Lai JK-H, Saw W-Y, Ong RT-H, Cheng AY, Pillai NE, et al. Insights into the genetic structure and diversity of 38 South Asian Indians from deep whole-genome sequencing. PLoS Genet. 2014;10(5):e1004377.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  70. 70.

    Chambers JC, Abbott J, Zhang W, Turro E, Scott WR, Tan S-T, et al. The South Asian genome. PLoS One. 2014;9(8):e102645.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  71. 71.

    Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  72. 72.

    Mallick S, Li H, Lipson M, Mathieson I, Gymrek M, Racimo F, et al. The Simons Genome Diversity Project: 300 genomes from 142 diverse populations. Nature. 2016;538(7624):201–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  73. 73.

    Mondal M, Casals F, Xu T, Dall’Olio GM, Pybus M, Netea MG, et al. Genomic analysis of Andamanese provides insights into ancient human migration into Asia and adaptation. Nat Genet. 2016;48(9):1066–70.

    CAS  PubMed  Article  Google Scholar 

  74. 74.

    Rustagi N, Zhou A, Watkins WS, Gedvilaite E, Wang S, Ramesh N, et al. Extremely low-coverage whole genome sequencing in South Asians captures population genomics information. BMC Genomics. 2017;18(1):396.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  75. 75.

    Malhotra S, Singh S, Sarkar S. Whole genome variant analysis in three ethnically diverse Indians. Genes Genomics. 2018;40(5):497–510.

    CAS  PubMed  Article  Google Scholar 

  76. 76.

    Hariprakash JM, Vellarikkal SK, Verma A, Ranawat AS, Jayarajan R, Ravi R, et al. SAGE: a comprehensive resource of genetic variants integrating South Asian whole genomes and exomes. Database (Oxford). 2018;2018:1–10.

    PubMed  Article  Google Scholar 

  77. 77.

    Almal S, Jeon S, Agarwal M, Patel S, Patel S, Bhak Y, et al. Sequencing and analysis of the whole genome of Indian Gujarati male. Genomics. 2019;111(2):196–204.

    CAS  PubMed  Article  Google Scholar 

  78. 78.

    Ahmed PH, V V, More RP, Viswanath B, Jain S, Rao MS, et al. INDEX-db: The Indian Exome Reference Database (Phase I). J Comput Biol. 2019;26(3):225–34.

    Article  CAS  Google Scholar 

  79. 79.

    Singh V, Jolly B, Rajput NK, Pramanik S, Bhardwaj A. MtBrowse: An integrative genomics browser for human mitochondrial DNA. Mitochondrion. 2019.

  80. 80.

    Vellarikkal SK, Dhiman H, Joshi K, Hasija Y, Sivasubbu S, Scaria V. mit-o-matic: a comprehensive computational pipeline for clinical evaluation of mitochondrial variations from next-generation sequencing datasets. Hum Mutat. 2015;36(4):419–24.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  81. 81.

    Upadhyay P, Gardi N, Desai S, Sahoo B, Singh A, Togar T, et al. TMC-SNPdb: an Indian germline variant database derived from whole exome sequences. Database (Oxford). 2016;2016:baw104.

    Article  CAS  Google Scholar 

  82. 82.

    An JY. National human genome projects: an update and an agenda. Epidemiol Health. 2017;39:e2017045.

    PubMed  PubMed Central  Article  Google Scholar 

  83. 83.

    Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, et al. Rare disease terminology and definitions—a systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value Health. 2015;18(6):906–14.

    PubMed  Article  PubMed Central  Google Scholar 

  84. 84.

    Orphan Drug Act. 1983. Accessed 23 May 2019.

  85. 85.

    Thomas S, Caplan A. The Orphan Drug Act Revisited. JAMA. 2019;321(9):833–4.

    PubMed  Article  PubMed Central  Google Scholar 

  86. 86.

    Šimerka P. Council Recommendation. Luxembourg; 2009. Accessed 28 Mar 2019

  87. 87.

    Passos-Bueno MR, Bertola D, Horovitz DD, de Faria Ferraz VE, Brito LA. Genetics and genomics in Brazil: a promising future. Mol Genet Genomic Med. 2014;2(4):280–91.

    PubMed  PubMed Central  Article  Google Scholar 

  88. 88.

    Hsu JC, Wu HC, Feng WC, Chou CH, Lai EC, Lu CY. Disease and economic burden for rare diseases in Taiwan: a longitudinal study using Taiwan’s National Health Insurance Research Database. PLoS One. 2018;13(9):e0204206.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  89. 89.

    Swaminathan S. ICMR Bulletin. New Delhi; 2017. Accessed 28 Ma 2019

  90. 90.

    Rajasimha HK, Shirol PB, Ramamoorthy P, Hegde M, Barde S, Chandru V, et al. Organization for rare diseases India (ORDI)—addressing the challenges and opportunities for the Indian rare diseases’ community. Genet Res (Camb). 2014;96:e009.

    Article  Google Scholar 

  91. 91.

    Ferreira CR. The burden of rare diseases. Am J Med Genet A. 2019;179(6):885–92.

  92. 92.

    Rare Diseases and Disorders. Accessed 28 Mar 2019.

  93. 93.

    Bhattacharya S, Katoch VM, Majumder PP, Bhattacharya A. Rare diseases In India: current knowledge and new possibilities. Proc Indian Natl Sci Acad. 2016;82(4):1183–7.

    Article  Google Scholar 

  94. 94.

    Kar A, Phadnis S, Dharmarajan S, Nakade J. Epidemiology and social costs of haemophilia in India. Indian J Med Res. 2014;140(1):19–31.

    PubMed  PubMed Central  Google Scholar 

  95. 95.

    Colah R, Italia K, Gorakshakar A. Burden of thalassemia in India: the road map for control. Pediatr Hematol Oncol J. 2017;2(4):79–84.

    Article  Google Scholar 

  96. 96.

    Gourie-Devi M. Epidemiology of neurological disorders in India: review of background, prevalence and incidence of epilepsy, stroke, Parkinson’s disease and tremors. Neurol India. 2014;62(6):588–98.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  97. 97.

    Molecular Diagnostics, Counseling, Care and Research Centre. Accessed 28 Mar 2019.

  98. 98.

    Bepari KK, Malakar AK, Paul P, Halder B, Chakraborty S. Allele frequency for Cystic fibrosis in Indians vis-a/-vis global populations. Bioinformation. 2015;11(7):348–52.

    PubMed  PubMed Central  Article  Google Scholar 

  99. 99.

    Lakhan R, Ekundayo OT, Shahbazi M. An estimation of the prevalence of intellectual disabilities and its association with age in rural and urban populations in India. J Neurosci Rural Pract. 2015;6(4):523–8.

    PubMed  PubMed Central  Article  Google Scholar 

  100. 100.

    Kulkarni ML, Samuel K, Bhagyavathi M, Sureshkumar C. Skeletal dysplasias in a hospital in southern India. Indian Pediatr. 1995;32(6):657–65.

    CAS  PubMed  Google Scholar 

  101. 101.

    Singh P, Mukherjee K. Cost-benefit analysis and assessment of quality of care in patients with hemophilia undergoing treatment at National Rural Health Mission in Maharashtra. India. Value Heal Reg issues. 2017;12:101–6.

    Article  Google Scholar 

  102. 102.

    Jadhav U, Mukherjee K. Assessment of healthcare measures, healthcare resource use, and cost of care among severe hemophilia A patients in Mumbai region of India. J Postgrad Med. 2018;64(3):138–44.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  103. 103.

    Moirangthem A, Phadke SR. Socio-demographic Profile and Economic Burden of Treatment of Transfusion Dependent Thalassemia. Indian J Pediatr. 2018;85(2):102–7.

    PubMed  Article  Google Scholar 

  104. 104.

    Kumar H, Sarma P, Medhi B. Orphan drugs: Indian perspective. Indian J Pharmacol. 2017;49:267–9.

    PubMed  PubMed Central  Article  Google Scholar 

  105. 105.

    Indian Rare Disease Registry. Accessed 28 Mar 2019.

  106. 106.

    Phadke S. Hemophilia care in India: a review and experience from a tertiary care centre in Uttar Pradesh. Indian J Hematol blood. 2011;27(3):121–6.

    Article  Google Scholar 

  107. 107.

    Jadhav U, Mukherjee K, Lalwani A. Ethical issues in the care of persons living with haemophilia in India. Indian J Med Ethics. 2014;11(4):223–7.

    PubMed  Google Scholar 

  108. 108.

    Hemophilia Federation (India). Accessed 28 Mar 2019.

  109. 109.

    Institute of Medical Genetics and Genomics. Accessed 28 Mar 2019.

  110. 110.

    Verma IC, Saxena R, Lall M, Bijarnia S, Sharma R. Genetic counseling and prenatal diagnosis in India--experience at Sir Ganga Ram Hospital. Indian J Pediatr. 2003;70(4):293–7.

    CAS  PubMed  Article  Google Scholar 

  111. 111.

    Muranjan M, Karande S. Enzyme replacement therapy in India: lessons and insights. J Postgrad Med. 2018;64:195–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  112. 112.

    Collins FS, McKusick VA. Implications of the Human Genome Project for medical science. JAMA. 2001;285(5):540–4.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  113. 113.

    Wilson BJ, Nicholls SG. The Human Genome Project, and recent advances in personalized genomics. Risk Manag Healthc Policy. 2015;8:9–20.

    PubMed  PubMed Central  Article  Google Scholar 

  114. 114.

    Brittain HK, Scott R, Thomas E. The rise of the genome and personalised medicine. Clin Med. 2017;17(6):545–51.

    Article  Google Scholar 

  115. 115.

    Chial H. DNA sequencing technologies key to the human genome project. Nat Educ. 2008;1(1):219.

    Google Scholar 

  116. 116.

    Heather JM, Chain B. The sequence of sequencers: the history of sequencing DNA. Genomics. 2016;107(1):1–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  117. 117.

    Shendure J, Balasubramanian S, Church GM, Gilbert W, Rogers J, Schloss JA, et al. DNA sequencing at 40: past, present and future. Nature. 2017;550(7676):345–53.

    CAS  PubMed  Article  Google Scholar 

  118. 118.

    van Dijk EL, Auger H, Jaszczyszyn Y, Thermes C. Ten years of next-generation sequencing technology. Trends Genet. 2014;30(9):418–26.

    PubMed  Article  CAS  Google Scholar 

  119. 119.

    Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016;17(6):333–51.

    CAS  PubMed  Article  Google Scholar 

  120. 120.

    Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10(1):57–63.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  121. 121.

    Necsulea A, Kaessmann H. Evolutionary dynamics of coding and non-coding transcriptomes. Nat Rev Genet. 2014;15(11):734–48.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  122. 122.

    Strobel EJ, Yu AM, Lucks JB. High-throughput determination of RNA structures. Nat Rev Genet. 2018;19(10):615–34.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  123. 123.

    Meaburn E, Schulz R. Next generation sequencing in epigenetics: insights and challenges. Semin Cell Dev Biol. 2012;23(2):192–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  124. 124.

    Mias GI, Snyder M. Personal genomes, quantitative dynamic omics and personalized medicine. Quant Biol. 2013;1(1):71–90.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  125. 125.

    Chen R, Snyder M. Promise of personalized omics to precision medicine. Wiley Interdiscip Rev Syst Biol Med. 2013;5(1):73–82.

    PubMed  Article  PubMed Central  Google Scholar 

  126. 126.

    Need AC, Shashi V, Hitomi Y, Schoch K, Shianna KV, McDonald MT, et al. Clinical application of exome sequencing in undiagnosed genetic conditions. J Med Genet. 2012;49(6):353–61.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  127. 127.

    Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet. 2013;14(10):681–91.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  128. 128.

    Might M, Wilsey M. The shifting model in clinical diagnostics: how next-generation sequencing and families are altering the way rare diseases are discovered, studied, and treated. Genet Med. 2014;16(10):736–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  129. 129.

    Lee H, Deignan JL, Dorrani N, Strom SP, Kantarci S, Quintero-Rivera F, et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA. 2014;312(18):1880–7.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  130. 130.

    Salk JJ, Schmitt MW, Loeb LA. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Genet. 2018;19(5):269–85.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  131. 131.

    Rare Disease Impact Report: Insights from patients and the medical community. Shire Human Genetic Therapies. 2013. Accessed 23 May 2019.

  132. 132.

    GUaRDIAN. Accessed 28 Mar 2019.

  133. 133.

    Kohler S, Doelken SC, Mungall CJ, Bauer S, Firth HV, Bailleul-Forestier I, et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Res. 2014;42(Database issue):D966–74.

    PubMed  Article  CAS  Google Scholar 

  134. 134.

    Baudhuin LM. Quality guidelines for next-generation sequencing. Clin Chem. 2013;59:858–9.

    CAS  PubMed  Article  Google Scholar 

  135. 135.

    Rehm HL, Bale SJ, Bayrak-Toydemir P, Berg JS, Brown KK, Deignan JL, et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013;15(9):733–47.

    PubMed  PubMed Central  Article  Google Scholar 

  136. 136.

    Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24.

    PubMed  PubMed Central  Article  Google Scholar 

  137. 137.

    OpenPGx. Accessed 23 May 2019.

  138. 138.

    Kandoi G, Nanda A, Scaria V, Sivasubbu S. A case for pharmacogenomics in management of cardiac arrhythmias. Indian Pacing Electrophysiol J. 2012;12(2):54–64.

    PubMed  PubMed Central  Article  Google Scholar 

  139. 139.

    Cambon-Thomsen A, Thorisson GA, Mabile L. The role of a bioresource research impact factor as an incentive to share human bioresources. Nat Gen. 2011;43:503–4.

    CAS  Article  Google Scholar 

  140. 140.

    Vellarikkal SK, Patowary A, Singh M, Kumari R, Faruq M, Master DC, et al. Exome sequencing reveals a novel mutation, p.L325H, in the KRT5 gene associated with autosomal dominant Epidermolysis Bullosa Simplex Koebner type in a large family from western India. Hum genome Var. 2014;1:14007.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  141. 141.

    Karuthedath Vellarikkal S, Jayarajan R, Verma A, Nair S, Ravi R, Senthivel V, et al. Case Report: Whole exome sequencing reveals a novel frameshift deletion mutation p.G2254fs in COL7A1 associated with autosomal recessive dystrophic epidermolysis bullosa. F1000Res. 2016;5:900.

    PubMed  PubMed Central  Article  Google Scholar 

  142. 142.

    Yenamandra VK, Vellarikkal SK, Kumar M, Chowdhury MR, Jayarajan R, Verma A, et al. Application of whole exome sequencing in elucidating the phenotype and genotype spectrum of junctional epidermolysis bullosa: a preliminary experience of a tertiary care centre in India. J Dermatol Sci. 2017;86(1):30–6.

    CAS  PubMed  Article  Google Scholar 

  143. 143.

    Yenamandra VK, Vellarikkal SK, Chowdhury MR, Jayarajan R, Verma A, Scaria V, et al. Genotype-phenotype correlations of dystrophic epidermolysis bullosa in India: experience from a tertiary care centre. Acta Derm Venereol. 2018;98(9):873–9.

    CAS  PubMed  Article  Google Scholar 

  144. 144.

    Sandhya P, Vellarikkal SK, Nair A, Ravi R, Mathew J, Jayarajan R, et al. Egyptian tale from India: application of whole-exome sequencing in diagnosis of atypical familial Mediterranean fever. Int J Rheum Dis. 2017;20(11):1770–5.

    CAS  PubMed  Article  Google Scholar 

  145. 145.

    Gupta A, Sharma Y, Deo K, Vellarikkal S, Jayarajan R, Dixit V, et al. Case Report: Whole exome sequencing helps in accurate molecular diagnosis in siblings with a rare co-occurrence of paternally inherited 22q12 duplication and autosomal recessive non-syndromic ichthyosis. F1000Res. 2015;4:446.

    PubMed  PubMed Central  Article  Google Scholar 

  146. 146.

    Gupta A, Sharma YK, Vellarikkal SK, Jayarajan R, Dixit V, Verma A, et al. Whole-exome sequencing solves diagnostic dilemma in a rare case of sporadic acrokeratosis verruciformis. J Eur Acad Dermatol Venereol. 2016;30:695–7.

    CAS  PubMed  Article  Google Scholar 

  147. 147.

    Narayanan R, Karuthedath Vellarikkal S, Jayarajan R, Verma A, Dixit V, Scaria V, et al. Case report: application of whole exome sequencing for accurate diagnosis of rare syndromes of mineralocorticoid excess. F1000Res. 2016;5:1592.

    PubMed  Article  Google Scholar 

  148. 148.

    Govindaraj GM, Karuthedath Vellarikkal S, Jayarajan R, Ravi R, Verma A, Chakkiyar K, et al. Case Report: Whole exome sequencing identifies variation c.2308G>A p.E770K in RAG1 associated with B- T- NK+ severe combined immunodeficiency. F1000Res. 2016;5:2532.

    PubMed  Article  Google Scholar 

  149. 149.

    Rawat A, Karuthedath Vellarikkal S, Verma A, Jayarajan R, Gupta A, Singh S, et al. Case Report: Whole exome sequencing identifies a novel frameshift insertion c.1325dupT (p.F442fsX2) in the tyrosine kinase domain of BTK gene in a young Indian individual with X-linked agammaglobulinemia. F1000Res. 2016;5:2667.

    PubMed  Article  Google Scholar 

  150. 150.

    Mg G, Riyaz A, Krishnan C, Scaria V. Rapid transition of facial features from early to mid-adolescence in autosomal dominant hyper IgE syndrome with a STAT3 Variation. Indian J Pediatri. 2018;85:595–6.

    Article  Google Scholar 

  151. 151.

    Virmani N, Vellarikkal SK, Verma A, Jayarajan R, Sakhiya J, Desai C, et al. Whole exome sequencing in a multi-generation family from India reveals a genetic variation c.10C>T (p.Gln4Ter) in keratin 5 gene associated with Dowling-Degos disease. Indian J Dermatol Venereol Leprol. 2018;84:344–6.

    PubMed  Google Scholar 

  152. 152.

    Vellarikkal SK, Jayarajan R, Verma A, Ravi R, Senthilvel V, Kumar A, et al. A founder mutation MLC1 c.736delA associated with megalencephalic leukoencephalopathy with subcortical cysts-1 in north Indian kindred. Clin Genet. 2018;94:271–3.

    CAS  PubMed  Article  Google Scholar 

  153. 153.

    Yenamandra VK, Shamsudheen KV, Madhumita RC, Rijith J, Ankit V, Scaria V, et al. Autosomal recessive epidermolysis bullosa simplex: report of three cases from India. Clin Exp Dermatol. 2017;42:800–3.

    CAS  PubMed  Article  Google Scholar 

  154. 154.

    Mahajan R, Vellarikkal SK, Handa S, Verma A, Jayarajan R, Kumar A, et al. Utility of whole-exome sequencing in detecting novel compound heterozygous mutations in COL7A1 among families with severe recessive dystrophic epidermolysis bullosa in India - implications on diagnosis, prognosis and prenatal testing. J Eur Acad Dermatol Venereol. 2018;32:e433–5.

    CAS  PubMed  Article  Google Scholar 

  155. 155.

    Hariprakash JM, Vellarikkal SK, Keechilat P, Verma A, Jayarajan R, Dixit V, et al. Pharmacogenetic landscape of DPYD variants in south Asian populations by integration of genome-scale data. Pharmacogenomics. 2018;19(3):227–41.

    CAS  PubMed  Article  Google Scholar 

  156. 156.

    Sivadas A, Salleh MZ, Teh LK, Scaria V. Genetic epidemiology of pharmacogenetic variants in South East Asian Malays using whole-genome sequences. Pharmacogenomics J. 2017;17(5):461–70.

    CAS  PubMed  Article  Google Scholar 

  157. 157.

    Sivadas A, Sharma P, Scaria V. Landscape of warfarin and clopidogrel pharmacogenetic variants in Qatari population from whole exome datasets. Pharmacogenomics. 2016;17(17):1891–901.

    CAS  PubMed  Article  Google Scholar 

  158. 158.

    Sivadas A, Scaria V. Pharmacogenomic survey of Qatari populations using whole-genome and exome sequences. Pharmacogenomics J. 2018;18(4):590–600.

    CAS  PubMed  Article  Google Scholar 

  159. 159.

    Koshy R, Ranawat A, Scaria V. al mena: a comprehensive resource of human genetic variants integrating genomes and exomes from Arab, Middle Eastern and North African populations. J Hum Genet. 2017;62(10):889–94.

    CAS  PubMed  Article  Google Scholar 

  160. 160.

    Jain A, Gandhi S, Koshy R, Scaria V. Incidental and clinically actionable genetic variants in 1005 whole exomes and genomes from Qatar. Mol Genet Genomics. 2018;293(4):919–29.

    CAS  PubMed  Article  Google Scholar 

  161. 161.

    Scaria V, Sivasubbu S. Exome Sequence Analysis and Interpretation: Handbook for Clinicians. 1st ed: The Readers Paradise; 2015. p. 200.

    Google Scholar 

  162. 162.

    Enns GM, Shashi V, Bainbridge M, Gambello MJ, Zahir FR, Bast T, et al. Mutations in NGLY1 cause an inherited disorder of the endoplasmic reticulum-associated degradation pathway. Genet Med. 2014;16(10):751–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  163. 163.

    Abouelhoda M, Sobahy T, El-Kalioby M, Patel N, Shamseldin H, Monies D, et al. Clinical genomics can facilitate countrywide estimation of autosomal recessive disease burden. Genet Med. 2016;18(12):1244–9.

    CAS  PubMed  Article  Google Scholar 

  164. 164.

    Kumari P, Joshi D, Shamal SN, Singh R. Study of dystrophinopathy in Eastern Uttar Pradesh population of India. J Pediatr Neurosci. 2018;13(2):182–8.

    PubMed  PubMed Central  Article  Google Scholar 

  165. 165.

    Basumatary LJ, Das M, Goswami M, Kayal AK. Deletion pattern in the dystrophin gene in Duchenne muscular dystrophy patients in northeast India. J Neurosci Rural Pract. 2013;4(2):227–9.

    PubMed  PubMed Central  Article  Google Scholar 

  166. 166.

    Singh R-J, Manjunath M, Preethish-Kumar V, Polavarapu K, Vengalil S, Thomas PT, et al. Natural history of a cohort of Duchenne muscular dystrophy children seen between 1998 and 2014: An observational study from South India. Neurol India. 2018;66(1):77–82.

    PubMed  Article  Google Scholar 

  167. 167.

    Sakthivel Murugan SM, Arthi C, Thilothammal N, Lakshmi BR. Carrier detection in Duchenne muscular dystrophy using molecular methods. Indian J Med Res. 2013;137(6):1102–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  168. 168.

    Vengalil S, Preethish-Kumar V, Polavarapu K, Mahadevappa M, Sekar D, Purushottam M, et al. Duchenne muscular dystrophy and Becker muscular dystrophy confirmed by multiplex ligation-dependent probe amplification: genotype-phenotype correlation in a large cohort. J Clin Neurol. 2017;13(1):91–7.

    PubMed  Article  Google Scholar 

  169. 169.

    Manjunath M, Kiran P, Preethish-Kumar V, Nalini A, Singh RJ, Gayathri N. A comparative study of mPCR, MLPA, and muscle biopsy results in a cohort of children with Duchenne muscular dystrophy: a first study. Neurol India. 2015;63(1):58–62.

    CAS  PubMed  Article  Google Scholar 

  170. 170.

    Deepha S, Vengalil S, Preethish-Kumar V, Polavarapu K, Nalini A, Gayathri N, et al. MLPA identification of dystrophin mutations and in silico evaluation of the predicted protein in dystrophinopathy cases from India. BMC Med Genet. 2017;18(1):67.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  171. 171.

    Singh B, Mandal K, Lallar M, Narayanan DL, Mishra S, Gambhir PS, et al. Next generation sequencing in diagnosis of MLPA negative cases presenting as Duchenne/Becker muscular dystrophies. Indian J Pediatr. 2018;85:309–10.

    PubMed  Article  Google Scholar 

  172. 172.

    Kadali S, Kolusu A, Gummadi MR, Undamatla J. The relative frequency of lysosomal storage disorders: a medical genetics referral laboratory’s experience from India. J Child Neurol. 2014;29(10):1377–82.

    PubMed  Article  Google Scholar 

  173. 173.

    Hebbar M, Prasada LH, Bhowmik A, Trujillano D, Shukla A, Chakraborti S, et al. Homozygous deletion of exons 2 and 3 of NPC2 associated with Niemann-Pick disease type C. Am J Med Gen Part A. 2016;170:2486–9.

    CAS  Article  Google Scholar 

  174. 174.

    Madkaikar M, Aluri J, Gupta S. Guidelines for screening, early diagnosis and management of severe combined immunodeficiency (SCID) in India. Indian J Pediatr. 2016;83(5):455–62.

    PubMed  Article  Google Scholar 

  175. 175.

    Jindal AK, Pilania RK, Rawat A, Singh S. Primary immunodeficiency disorders in India—a situational review. Front Immunol. 2017;8:714.

    PubMed  PubMed Central  Article  Google Scholar 

  176. 176.

    Gupta M, Aluri J, Desai M, Lokeshwar M, Taur P, Lenardo M, et al. Clinical, immunological, and molecular findings in four cases of B cell expansion with NF-kappaB and T cell anergy disease for the first time from India. Front Immunol. 2018;9:1049.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  177. 177.

    Aluri J, Desai M, Gupta M, Dalvi A, Terance A, Rosenzweig SD, et al. Clinical, immunological, and molecular findings in 57 patients with severe combined immunodeficiency (SCID) from India. Front Immunol. 2019;10:23.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  178. 178.

    Aluri J, Gupta M, Dalvi A, Mhatre S, Kulkarni M, Hule G, et al. Clinical, immunological, and molecular findings in five patients with major histocompatibility complex class II deficiency from India. Front Immunol. 2018;9:188.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  179. 179.

    Sonam K, Bindu PS, Srinivas Bharath MM, Govindaraj P, Gayathri N, Arvinda HR, et al. Mitochondrial oxidative phosphorylation disorders in children: phenotypic, genotypic and biochemical correlations in 85 patients from South India. Mitochondrion. 2017;32:42–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  180. 180.

    Vinu N, Puri RD, Anand K, Verma IC. Expanding the phenotype of the founder South Asian mutation in the nuclear encoding mitochondrial RMND1 Gene. Indian J Pediatr. 2018;85(2):87–92.

    CAS  PubMed  Article  Google Scholar 

  181. 181.

    Srivastava A, Srivastava KR, Hebbar M, Galada C, Kadavigrere R, Su F, et al. Genetic diversity of NDUFV1-dependent mitochondrial complex I deficiency. Eur J Hum Genet. 2018;26(11):1582–7.

    CAS  PubMed  Article  Google Scholar 

  182. 182.

    Dalal A, Das BA, Agarwal D, Phadke SR. Exome sequencing & homozygosity mapping for identification of genetic aetiology for spastic ataxia in a consanguineous family. Indian J Med Res. 2015;142:220–4.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  183. 183.

    Faruq M, Narang A, Kumari R, Pandey R, Garg A, Behari M, et al. Novel mutations in typical and atypical genetic loci through exome sequencing in autosomal recessive cerebellar ataxia families. Clin Genet. 2014;86(4):335–41.

    CAS  PubMed  Article  Google Scholar 

  184. 184.

    Uttarilli A, Shah H, Bhavani GS, Upadhyai P, Shukla A, Girisha KM. Phenotyping and genotyping of skeletal dysplasias: evolution of a center and a decade of experience in India. Bone. 2019;120:204–11.

    PubMed  Article  PubMed Central  Google Scholar 

  185. 185.

    Girisha KM, Kortum F, Shah H, Alawi M, Dalal A, Bhavani GS, et al. A novel multiple joint dislocation syndrome associated with a homozygous nonsense variant in the EXOC6B gene. Eur J Hum Genet. 2016;24(8):1206–10.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  186. 186.

    Das Bhowmik A, Dalal A, Matta D, Kandadai RM, Kanikannan MA, Aggarwal S. Identification of a novel splice site HSPG2 mutation and prenatal diagnosis in Schwartz Jampel Syndrome type 1 using whole exome sequencing. Neuromuscul Disord. 2016;26(11):809–14.

    PubMed  Article  Google Scholar 

  187. 187.

    Rai E, Mahajan A, Kumar P, Angural A, Dhar MK, Razdan S, et al. Whole exome screening identifies novel and recurrent WISP3 mutations causing progressive pseudorheumatoid dysplasia in Jammu and Kashmir-India. Sci Rep. 2016;6:27684.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  188. 188.

    Genomics and other Omics tools for Enabling Medical Decision. Accessed 28 Mar 2019.

  189. 189.

    Kar B, Sivamani S. Directory of genetic test services and counselling centres in India. Int J Hum Genet. 2016;16(3–4):148–57.

    Article  Google Scholar 

  190. 190.

    India Newborn Action Plan - National Health Mission. Accessed 28 Mar 2019.

  191. 191.

    Chakrabarty S, Kabekkodu SP, Brand A, Satyamoorthy K. Perspectives on translational genomics and public health in India. Public Health Genomics. 2016;19(2):61–8.

    PubMed  Article  Google Scholar 

  192. 192.

    Puri RD, Kabra M. Editorial: new horizons in genetic diagnosis in pediatric practice: the excitement and challenges! Indian J Pediatr. 2016;83:1131–2.

    PubMed  Article  Google Scholar 

  193. 193.

    National Policy For Treatment Of Rare Diseases. 2017. Diseases Policy FINAL.pdf. Accessed 28 Mar 2019.

  194. 194.

    Rare disease cell order. 2018. Accessed 28 Mar 2019.

  195. 195.

    Rivas MA, Avila BE, Koskela J, Huang H, Stevens C, Pirinen M, et al. Insights into the genetic epidemiology of Crohn’s and rare diseases in the Ashkenazi Jewish population. PLoS Genet. 2018;14(5):e1007329.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  196. 196.

    Genome Asia 100K. Accessed 28 Mar 2019.

  197. 197.

    First PM-STIAC Meet. Accessed 28 Mar 2019.

  198. 198.

    IndiGen 2019. Accessed 23 May 2019.

Download references


The GUaRDIAN Consortium is very grateful to all the patients, family members, and patient support groups for their active participation and cooperation during the course of the research study. The authors also thank the hospitals, clinical and research fraternity for joining hands together to solve the rare disease mysteries in India. SS and VS thank CSIR and IGIB for constant support and encouragement. SS and VS thank M/S Sanofi Genzyme Pvt Ltd. for the unrestricted educational grant that permitted training of medical professionals in the area of tclinical genomics.

The GUaRDIAN Consortium:

Anjali Bajaj$, Samatha Mathew$, Shamsudheen Karuthedath Vellarikkal, Ambily Sivadas, Rahul C Bhoyar, Kandarp Joshi, Abhinav Jain, Anushree Mishra, Ankit Verma, Rijith Jayarajan, A Nalini, A Ravi Kumar, A.T Arasar Seeralar, Aayush Gupta, Achal K Srivastava, Aditi Joshi, Aditi Sinha, Aditya Jandial, Afreen Khan, Akhilesh K Sonakar, Alex Chandy, Aman Sharma, Ambuj Roy, Amit Rawat, Amitabh Biswas, Andrew Vanlalawma, Anita Chaudhary, Anita Chopra, Ankit Panday, Ankit Sabharwal, Ankita Mitra, Ankita Narang, Anna Rajab, Anoop Kumar, Anoop Singh Gurjar, Anop Singh Ranawat, Anu R I, Anup Kumar Tiwary, Anuradha, Aquil Kalanad, Aradhana Mathur, Arjun Lakshman, Arushi Batra, Arvind Bagga, Ashish Aggarwal, Ashok Gupta, Ashu Rastogi, Aslam PK, Astha V, Aswin Nair, Athulya E P, Atri Chatterjee, Atul Jindal, Atul Kumar Kashyap, B Priyadarshini, Babu Ram Thapa, Balram Bhargava, Balram Sharma, Bani Jolly, Bharath Ram Uppilli, Bharathi Balachander, Bhim Shankar, Bibhas Kar, Binukumar B K, C. Lalchhandama, Chaitanya Datar, Chetana Sachidanandan, D C Master, Daisy Khera, Debashish Chowdhury, Debashish Danda, Deepak Kumar, Deepika Pandhi, Deepti Siddharthan, Disha Sharma, Divya Pachat, Brijesh Sharma, Durga Rao Vegulada, GSRSNK Naidu, G Padma, G.Vishnu Priya, Gautam Sharma, Gauthamen R, Geeta Govindaraj, George M Varghese, Gireesh S, GopiKrishnan Unnikrishnan, Hafiz SA, Hazeena KR, Heena Dhiman, Hema Singh, Hrishikesh Sarkar, Istaq Ahmed, Jagadeesh Menon, Jatinder Goraya, Jennifer Mathew, Jineesh Thottath, Jitendra K Sahu, Jitendra Oswal, John Menachery, Judith Mary Hariprakash, K Bhargava, K K Talwar, K M Cherian, K P Aravindan, K Pramila, K Saroja, K Shantaraman, Kavita Pandhare, Kiran Kumar Mandapati, Kiran P, Kotha Rakesh, Krati Shah, Krishnan C, Kriti Shah, Kuldeep Singh, Kuljeet Anand, Lalawmpuii Pachuau, Laxmisha Chandrashekar, Liza Rajasekhar, Lopamudra Mishra, M V Padma, Madhulika Kabra, Madhumita Roy Chowdhary, Malika Seth, Maneesh Rai, Manish Kumar, Manish Parakh, Manisha Goyal, Manisha Gurjar, Manisha Sahay, Mercy Rophina, Mitali Mukerji, Mohammed Ali, Mohammed Faruq, Mohandas Nair Karippoth, Mohit Kumar Divakar, MP Jayakrishnan, Mukesh Kumar, Mukta Poojary, Mukund A Prabhu, Nachimuthu Senthil Kumar, Nadeem Rais, Nalini Bhaskaranand, Narendra Kumar Bagri, Naveen Sankhyan, Neeraj Awasthy, Neeraj Gupta, Neeraj Parakh, Neerja Gupta, Neetu Bhari, Neetu Kushwaha, Neha Sharma, Neha Virmani, Nilanjan Kundu, Nishad Plakkal, Nishu Tyagi, Nita Radhakrishnan, Nitish Naik, Nitish Rai, Nivedita Mondal, Nupur Bhargava, Pankaj Hari, Paras Sehgal, Piyush Kumar, Pooja Chauhan, Pooja Mailankody, Pooja Sharma, Poonam Parakh, Pragya A Nair, Praloy Chakraborty, Prasanna Kumar Shirol, Pratibha Singh, Pratosh Gangadhar, Prawin Kumar, Purna chandra, R Krishnan, R Srilakshmi, R Sriranga Lakshmi, R. Anantharaman, Radha Mahadevan, Rahul Mahajan, Rajasubramaniam Shanmugam, Rajat Sharma, Rajendran V R, Rajinder K Dhamija, Rajit Pillai Ramanan, Rajive Kumar, Rajneesh A R, Rajnish Juneja, Rakesh Aggarwal, Rakesh Sahay, Ramakrishnan S, Ranjith Narayanan, Ravindra Shukla, Remya Koshy, Renu Kumari, Richa Chaudhary, Richa Jain, Riyaz Arakkal, Roopa Rajan, Rowmika Ravi, S Baruah, S. Sitaraman, Sadandandavalli Retnaswami Chandra, Saia Chenkual, Sailaja V, Sakshi Ambawat, Samhita Panda, Sana Zahra, Sanchit Kumar, Sandeep Arora, Sandeep Mathur, Sandeep Seth, Sandhya P, Sangam Goswami, Sangita Paul, Sanjay Pandey, Santharaman Kalyanaraman, Saroj Patnaik, Saruchi Wadhwa, Sathi Venu, Satyan Nanda, Saumya Panda, Saurabh Chopra, Saurabh Singh, Savinitha P, Seema Kapoor, Sesh Sivadasan, Sethuraman G, Shaista Parveen Khan, Shaji CV, Shanmugam Gurusamy, Sheffali Gulati, Shrey Gandhi, Sivaprakash Ramalingam, Smita Nath, Somesh Kumar, Sona Sathian, Sonal Lakhani, Soumya S Nair, Soumya Sundaram, Sourav Ghosh, Sree Bhushan Raju, Sreejith Valappil, Sreelata Nair, Srikanth Kadyada Puttaiah, Sruthi S Nair, Suja K Geevarghese, Sujata Mohanty, Sujay Khandpur, Suman Jain, Sumeet, Sumit Sharma, Suruchi Trehan, Suvasini Sharma, Sweta Jain, Swetha Jain, Tarun Kumar Badam, Umamaheswari S, Utkarsh Gaharwar, Uzma Shamim, Vadlamudi Raghavendra Rao, Vamsi Krishna, Vandana Jain, Varun Suroliya, Varuna Vyas, Veena Vedartham, Venketesh S, Vigneshwar Senthivel, Vijaykumar Bhavi, Vilas Jadhav, Vinay Gera, Vishal Dixit, Vishal Gupta, Vishnu Agarwal, Vishnu V Y, Vishu Gupta, Vysakha K V, Yugal K Sharma, Samir K Brahmachari, Vinod Scaria*, Sridhar Sivasubbu*. $These authors contributed equally.


The rare disease program at CSIR-IGIB is funded through the following research grants from the Council of Scientific and Industrial Research (CSIR), India 2012–2016: grant no. BSC0212 and BSC0122; September 2016 onwards: grant no. MLP1601; July 2018 onwards: grant nos. MLP1801, MLP1802, and MLP1809.

Author information





All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Sridhar Sivasubbu or Vinod Scaria.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

  1. I.

    Sridhar Sivasubbu and Vinod Scaria have received an unrestricted educational grant from M/S Sanofi Genzyme Pvt Ltd. for training medical professionals in the area of clinical genomics.

  2. II.

    Sridhar Sivasubbu and Vinod Scaria collaborate with M/S Adams Genetics Pvt Ltd. and M/S Genique Lifesciences Pvt Ltd. for developing technologies for interpretation of genome-scale datasets.

  3. III.

    Sridhar Sivasubbu, Vinod Scaria, and Md Faruq have developed and transferred molecular assays for diagnosis of genetic diseases to M/S Lal Path Labs Pvt Ltd.

  4. IV.

    Sridhar Sivasubbu and Vinod Scaria have developed and transferred NGS-based assays and computational reporting engine for diagnosis of mitochondrial diseases to M/S Eurofins Clinical Genetics India Pvt Ltd.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

The GUaRDIAN Consortium., Sivasubbu, S. & Scaria, V. Genomics of rare genetic diseases—experiences from India. Hum Genomics 13, 52 (2019).

Download citation


  • Rare disease
  • Genomics
  • India
  • Genetic diversity
  • Diagnostics
  • Zebrafish
  • IPSCs
  • Patient support